1. Home
  2. AKRO
  3. AKRO News

Latest Akero Therapeutics Inc. (AKRO) News on February 22, 2025

Akero Therapeutics, Inc. (AKRO): the Best Performing Healthcare Stock So Far in 2025
AKRO

Insider Monkey

3 days ago

Akero Therapeutics, Inc. (AKRO): the Best Performing Healthcare Stock So Far in 2025

AKRO

MT Newswires

10 days ago

Akero Therapeutics Insider Sold Shares Worth $1,581,994, According to a Recent SEC Filing

AKRO

MT Newswires

13 days ago

Akero Therapeutics Insider Bought Shares Worth $9,600,000, According to a Recent SEC Filing

AKRO

MT Newswires

17 days ago

Akero Therapeutics Insider Sold Shares Worth $538,061, According to a Recent SEC Filing

Why Akero Therapeutics Inc (AKRO) Is Skyrocketing So Far In 2025
AKRO

Insider Monkey

19 days ago

Why Akero Therapeutics Inc (AKRO) Is Skyrocketing So Far In 2025

Akero Therapeutics Inc. (AKRO): Among The Stocks That Started The Year On A High
AKRO

Insider Monkey

19 days ago

Akero Therapeutics Inc. (AKRO): Among The Stocks That Started The Year On A High

This Stock Just Doubled in 1 Day -- Is It Still a Buy?
AKRO

Motley Fool

20 days ago

This Stock Just Doubled in 1 Day -- Is It Still a Buy?

Why Akero Therapeutics (AKRO) Is Among the Best Booming Stocks to Invest in Now?
AKRO

Insider Monkey

20 days ago

Why Akero Therapeutics (AKRO) Is Among the Best Booming Stocks to Invest in Now?

AKRO

MT Newswires

22 days ago

UBS Adjusts Price Target on Akero Therapeutics to $109 From $42, Keeps Buy Rating

AKRO

MT Newswires

22 days ago

Akero Therapeutics Insider Sold Shares Worth $2,734,212, According to a Recent SEC Filing

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
AKRO

GlobeNewswire

23 days ago

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics
AKRO

Zacks

23 days ago

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics

AKRO

MT Newswires

23 days ago

BofA Securities Upgrades Akero Therapeutics to Buy, $63 Price Target

AKRO

MT Newswires

24 days ago

Akero Therapeutics Insider Sold Shares Worth $1,742,958, According to a Recent SEC Filing

AKRO

MT Newswires

24 days ago

Akero Therapeutics Insider Sold Shares Worth $1,646,978, According to a Recent SEC Filing

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
AKRO

Zacks

24 days ago

Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates

AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
AKRO

Zacks

24 days ago

AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study

BioAge drops obesity drug; Akero, 89bio cash in on MASH data
AKRO

BioPharma Dive

24 days ago

BioAge drops obesity drug; Akero, 89bio cash in on MASH data

AKRO

MT Newswires

24 days ago

Akero Therapeutics Prices $350 Million Upsized Public Offering

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
AKRO

GlobeNewswire

25 days ago

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Akero’s cirrhosis treatment shows promise in Phase IIb study
AKRO

Clinical Trials Arena

25 days ago

Akero’s cirrhosis treatment shows promise in Phase IIb study

Why Akero Therapeutics Inc. (AKRO) Surged on Monday
AKRO

Insider Monkey

25 days ago

Why Akero Therapeutics Inc. (AKRO) Surged on Monday

AKRO

MT Newswires

a month ago

Akero Therapeutics Starts $300 Million Stock Offering

Akero Therapeutics Stock Nearly Doubles — Pulling 89bio Higher — On Positive MASH Study
AKRO

Investor's Business Daily

a month ago

Akero Therapeutics Stock Nearly Doubles — Pulling 89bio Higher — On Positive MASH Study

Akero Therapeutics Announces Proposed Public Offering of Common Stock
AKRO

GlobeNewswire

a month ago

Akero Therapeutics Announces Proposed Public Offering of Common Stock

AKRO

GuruFocus.com

a month ago

Akero's Stock Skyrockets 112% After Game-Changing Liver Drug Data

Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results
AKRO

Investopedia

a month ago

Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results

Akero Therapeutics Shares Surge 106% as Phase 2b Study Shows Significant Cirrhosis Reversal
AKRO

GuruFocus.com

a month ago

Akero Therapeutics Shares Surge 106% as Phase 2b Study Shows Significant Cirrhosis Reversal

Akero Therapeutics Stock Doubles on Liver Data
AKRO

Barrons.com

a month ago

Akero Therapeutics Stock Doubles on Liver Data

AKRO

MT Newswires

a month ago

Sector Update: Health Care Stocks Mixed Premarket Monday

Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why
AKRO

Benzinga

a month ago

Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why

AKRO

MT Newswires

a month ago

Sector Update: Health Care

AKRO

MT Newswires

a month ago

Akero Therapeutics Says Phase 2b Efruxifermin Study Shows 'Statistically Significant' Reversal of Cirrhosis

AKRO

MT Newswires

a month ago

Top Premarket Gainers

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study
AKRO

GlobeNewswire

a month ago

Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
AKRO

GlobeNewswire

a month ago

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD
AKRO

GlobeNewswire

a month ago

Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD

Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
AKRO

GlobeNewswire

a month ago

Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

AKRO

MT Newswires

2 months ago

Akero Therapeutics Insider Sold Shares Worth $280,330, According to a Recent SEC Filing

Why Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
AKRO

Insider Monkey

3 months ago

Why Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference
AKRO

GlobeNewswire

3 months ago

Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference

AKRO

MT Newswires

3 months ago

Citigroup Initiates Akero Therapeutics at Buy With $65 Price Target

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
AKRO

GlobeNewswire

3 months ago

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

Akero Therapeutics to Present at the Jefferies London Healthcare Conference
AKRO

GlobeNewswire

3 months ago

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

Akero Therapeutics Advances in MASH Treatment Trials
AKRO

TipRanks

3 months ago

Akero Therapeutics Advances in MASH Treatment Trials

AKRO

MT Newswires

3 months ago

Akero Therapeutics' Q3 Net Loss Widens

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
AKRO

GlobeNewswire

3 months ago

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

AKRO

MT Newswires

4 months ago

Akero Therapeutics Insider Sold Shares Worth $3,438,312, According to a Recent SEC Filing

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH
AKRO

TipRanks

4 months ago

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
AKRO

GlobeNewswire

4 months ago

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

State Street Corp's Strategic Reduction in Akero Therapeutics Inc Shares
AKRO

GuruFocus.com

4 months ago

State Street Corp's Strategic Reduction in Akero Therapeutics Inc Shares

Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin
AKRO

Insider Monkey

4 months ago

Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin

Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds
AKRO

Insider Monkey

4 months ago

Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
AKRO

GlobeNewswire

5 months ago

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

Wellington Management Group LLP's Strategic Acquisition in Akero Therapeutics Inc
AKRO

GuruFocus.com

5 months ago

Wellington Management Group LLP's Strategic Acquisition in Akero Therapeutics Inc

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
AKRO

GlobeNewswire

5 months ago

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

Akero Therapeutics, Inc. (AKRO): This Small-Cap Healthcare Stock Is A Good Buy Right Now
AKRO

Insider Monkey

6 months ago

Akero Therapeutics, Inc. (AKRO): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
AKRO

GlobeNewswire

6 months ago

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

AKRO

MT Newswires

6 months ago

Akero Therapeutics Insider Sold Shares Worth $386,714, According to a Recent SEC Filing

AKRO

MT Newswires

6 months ago

Akero Therapeutics Shares Fall After Q2 Loss Widens

Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated
AKRO

Zacks

6 months ago

Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated

Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
AKRO

Zacks

6 months ago

Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
AKRO

GlobeNewswire

6 months ago

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised
AKRO

Zacks

7 months ago

Zoetis (ZTS) Q2 Earnings & Revenues Beat, '24 Outlook Raised

AKRO

MT Newswires

7 months ago

Akero Therapeutics Insider Sold Shares Worth $4,381,867, According to a Recent SEC Filing

Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade
AKRO

Zacks

7 months ago

Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade

AKRO

MT Newswires

8 months ago

Wolfe Research Initiates Coverage on Akero Therapeutics With Outperform Rating, $40 Price Target

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
AKRO

GlobeNewswire

8 months ago

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
AKRO

GlobeNewswire

8 months ago

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
AKRO

Zacks

9 months ago

Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
AKRO

GlobeNewswire

9 months ago

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

AKRO

MT Newswires

9 months ago

Evercore ISI Adjusts Price Target on Akero Therapeutics to $38 From $50, Maintains Outperform Rating

Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...
AKRO

GuruFocus.com

9 months ago

Akero Therapeutics Inc (AKRO) Q1 2024 Earnings: Misses Analyst Forecast Amid Continued ...

AKRO

MT Newswires

9 months ago

Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027

Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
AKRO

GlobeNewswire

9 months ago

Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference
AKRO

GlobeNewswire

9 months ago

Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
AKRO

GlobeNewswire

10 months ago

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks
AKRO

Insider Monkey

a year ago

Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks

Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That
AKRO

The Wall Street Journal

a year ago

Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That

Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
AKRO

Zacks

a year ago

Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH

Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
AKRO

Zacks

a year ago

Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
AKRO

GlobeNewswire

a year ago

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
AKRO

GlobeNewswire

a year ago

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

President and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO)
AKRO

GuruFocus.com

a year ago

President and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO)

Akero Therapeutics Announces Pricing of Public Offering of Common Stock
AKRO

GlobeNewswire

a year ago

Akero Therapeutics Announces Pricing of Public Offering of Common Stock

Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
AKRO

Zacks

a year ago

Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study

Akero Therapeutics Announces Proposed Public Offering of Common Stock
AKRO

GlobeNewswire

a year ago

Akero Therapeutics Announces Proposed Public Offering of Common Stock

Why Akero Rocketed — And Pulled Rival 89bio Higher — On Results In Liver Disease Treatment
AKRO

Investor's Business Daily

a year ago

Why Akero Rocketed — And Pulled Rival 89bio Higher — On Results In Liver Disease Treatment

Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs
AKRO

The Wall Street Journal

a year ago

Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs

Akero Therapeutics Bats Back Challenge From Lilly in Emerging Liver-Drug Market
AKRO

Barrons.com

a year ago

Akero Therapeutics Bats Back Challenge From Lilly in Emerging Liver-Drug Market

Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
AKRO

Investor's Business Daily

a year ago

Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment

AKRO

Reuters

a year ago

UPDATE 1-Akero's lead drug helps reduce scarring in fatty liver disease patients

AKRO

Reuters

a year ago

Akero's lead drug helps improve scarring in fatty liver disease patients

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
AKRO

GlobeNewswire

a year ago

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

Akero strengthens MASH drug’s case with new study data
AKRO

BioPharma Dive

a year ago

Akero strengthens MASH drug’s case with new study data

Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know
AKRO

Zacks

a year ago

Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know

Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
AKRO

GlobeNewswire

a year ago

Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH

Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AKRO

GlobeNewswire

a year ago

Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Are Medical Stocks Lagging GSK PLC Sponsored ADR (GSK) This Year?
AKRO

Zacks

a year ago

Are Medical Stocks Lagging GSK PLC Sponsored ADR (GSK) This Year?

Here's Why Akero Therapeutics, Inc. (AKRO) Is a Great 'Buy the Bottom' Stock Now
AKRO

Zacks

a year ago

Here's Why Akero Therapeutics, Inc. (AKRO) Is a Great 'Buy the Bottom' Stock Now

Share on Social Networks: